Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia

The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters.

<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Published Version</td>
<td>doi:10.1084/jem.20131033</td>
</tr>
<tr>
<td>Accessed</td>
<td>June 19, 2017 8:06:26 PM EDT</td>
</tr>
<tr>
<td>Citable Link</td>
<td><a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347397">http://nrs.harvard.edu/urn-3:HUL.InstRepos:13347397</a></td>
</tr>
<tr>
<td>Terms of Use</td>
<td>This article was downloaded from Harvard University's DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at <a href="http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA">http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA</a></td>
</tr>
</tbody>
</table>

(Article begins on next page)
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia

Marcus Järås,1,2 Peter G. Miller,1 Lisa P. Chu,1 Rishi V. Puram,1 Emma C. Fink,1 Rebekka K. Schneider,1 Fatima Al-Shahrour,1 Pablo Peña,2 L. Jordan Breyfogle,1 Kimberly A. Hartwell,1,3 Marie E. McConkey,1 Glenn S. Cowley,3 David E. Root,3 Michael G. Kharas,4,5 Ann Mullally,1 and Benjamin L. Ebert1,3

Despite extensive insights into the underlying genetics and biology of acute myeloid leukemia (AML), overall survival remains poor and new therapies are needed. We found that casein kinase 1α (Csnk1a1), a serine–threonine kinase, is essential for AML cell survival in vivo. Normal hematopoietic stem and progenitor cells (HSPCs) were relatively less affected by shRNA-mediated knockdown of Csnk1a1. To identify downstream mediators of Csnk1a1 critical for leukemia cells, we performed an in vivo pooled shRNA screen and gene expression profiling. We found that Csnk1a1 knockdown results in decreased Rps6 phosphorylation, increased p53 activity, and myeloid differentiation. Consistent with these observations, p53-null leukemias were insensitive to Csnk1a1 knockdown. We further evaluated whether D4476, a casein kinase 1 inhibitor, would exhibit selective antileukemic effects. Treatment of leukemia stem cells (LSCs) with D4476 showed highly selective killing of LSCs over normal HSPCs. In summary, these findings demonstrate that Csnk1a1 inhibition causes reduced Rps6 phosphorylation and activation of p53, resulting in selective elimination of leukemia cells, revealing Csnk1a1 as a potential therapeutic target for the treatment of AML.

© 2014 Järås et al. This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/3.0/).
Csnk1a1 is a therapeutic target in AML | Järås et al.

that are essential for the leukemia cells, although this finding was not validated (Miller et al., 2013). We therefore first tested the knockdown efficiency and antileukemia efficacy of individual Csnk1a1 shRNAs. We identified three distinct shRNAs that decreased the expression of Csnk1a1 mRNA and protein by >60% (Fig. 1A and B). To examine whether Csnk1a1 is essential for primary mouse MLL-AF9 leukemia cells in vivo, we used lentiviruses that coexpress individual shRNAs with GFP to transduce MLL-AF9 leukemia cells that were enriched for leukemia stem cells (LSCs) by sorting for c-Kit

followed the percentage of GFP+ leukemia cells over time. Based on findings from three independent shRNAs targeting Csnk1a1, we found that leukemia cells with Csnk1a1 knockdown were depleted 15–to 40-fold over a 2-wk period in both the spleen and BM, compared with cells expressing control shRNA (Fig. 1 C), without any defect in BM homing (Fig. 1 D).

To examine the effect of the same shRNAs on normal hematopoiesis, we expressed the Csnk1a1 shRNAs in Lin-Sca-1+Kit+ (LSK) hematopoietic stem and progenitor cells (HSPCs) and transplanted the cells into recipient mice. In contrast to the profound depletion observed in leukemia cells after
express GFP, and therefore Csnk1a1 or control shRNAs expressed from the same lentiviral vector, were purified and transplanted into recipient mice. Mice injected with leukemia cells expressing Csnk1a1 shRNAs lived significantly longer than control mice (Fig. 1 G). In aggregate, these data demonstrate that the MLL-AF9 leukemia cells are dependent on Csnk1a1 kinase function for growth and survival.

To determine the molecular mechanisms underlying the critical role of Csnk1a1 in leukemia, we performed an in vivo pooled shRNA screen on genes implicated as direct or indirect downstream targets of Csnk1a1 signaling. In this screen, 28 genes targeted by 149 shRNAs and 8 control shRNAs lacking endogenous target sequences were included (Table S1). The top hit in this screen was ribosomal protein S6 (Rps6; Fig. 2 A). Suppression of Rps6 with three independent shRNAs resulted in a dramatic depletion of leukemia cells in both spleen and BM over a 2-wk period (Fig. 2 B). All three hairpins targeting Rps6 showed successful knockdown of the Rps6 transcript (Fig. 2 C).

To address the possibility that our results were caused by off-target effects of the shRNAs, we generated an shRNA-resistant Csnk1a1 cDNA in which multiple silent mutations were introduced at the shRNA-binding sites. Coexpression of this shRNA-resistant cDNA successfully rescued the depletion of leukemia cells expressing Csnk1a1 shRNAs (Fig. 1 F).

Because inhibition of kinase activity is the most straightforward way to target Csnk1a1 pharmacologically, we tested whether the kinase function of Csnk1a1 is essential for leukemia cells. We introduced a known mutation that inactivates the kinase domain (Csnk1a1(D136N); Peters et al., 1999; Davidson et al., 2005; Bidère et al., 2009) into the shRNA-resistant Csnk1a1 cDNA. We found that the kinase-dead cDNA did not rescue the effect of the Csnk1a1 shRNAs, demonstrating that Csnk1a1 kinase function is essential for leukemia cells (Fig. 1 F).

We next examined whether suppression of Csnk1a1 could increase the survival of leukemic mice. Leukemia cells that express GFP, and therefore Csnk1a1 or control shRNAs expressed from the same lentiviral vector, were purified and transplanted into recipient mice. Mice injected with leukemia cells expressing Csnk1a1 shRNAs lived significantly longer than control mice (Fig. 1 G). In aggregate, these data demonstrate that the MLL-AF9 leukemia cells are dependent on Csnk1a1 kinase function for growth and survival.

To determine the molecular mechanisms underlying the critical role of Csnk1a1 in leukemia, we performed an in vivo pooled shRNA screen on genes implicated as direct or indirect downstream targets of Csnk1a1 signaling. In this screen, 28 genes targeted by 149 shRNAs and 8 control shRNAs lacking endogenous target sequences were included (Table S1). The top hit in this screen was ribosomal protein S6 (Rps6; Fig. 2 A). Suppression of Rps6 with three independent shRNAs resulted in a dramatic depletion of leukemia cells in both spleen and BM over a 2-wk period (Fig. 2 B). All three hairpins targeting Rps6 showed successful knockdown of the Rps6 transcript (Fig. 2 C).

RPS6 activity is regulated by phosphorylation by CSNK1A1, which phosphorylates serine residue 247, enhancing the phosphorylation of upstream sites (Hutchinson et al., 2011), as well as by the ribosomal S6 kinases 1 and 2 (Magnuson et al., 2012).
Figure 3. Csnk1a1 suppression activates a p53 response. (A) In leukemia cells with shRNA-mediated suppression of Csnk1a1, p53 signatures are enriched by GSEA. (B) Western blot demonstrating induced p53 and p21 expression after shRNA-mediated silencing of Csnk1a1 in leukemia cells. Actin was used as an endogenous control. (C) In leukemia cells with Csnk1a1 suppressed, up-regulated genes were enriched in a myeloid differentiation signature (left), and down-regulated genes were enriched in a hematopoietic stem cell (HSC) versus GMP down signature, i.e., a signature of genes down-regulated in GMPs relative to HSCs. (D) Histogram depicting c-Kit expression 72 h after transductions with shRNA-expressing lentiviral vectors. (** MLL-AF9

Csnk1a1 is a therapeutic target in AML | Järås et al.
Total Rps6 protein levels were not changed after Csnk1a1 suppression in leukemia, we performed gene expression profiling. We found that Csnk1a1 knockdown significantly increased expression of a p53 signature (Fig. 3 A; Kanesihia et al., 2012). Western blot analysis confirmed increased p53 and p21 expression (Fig. 3 B). In addition, we found that knockdown of Csnk1a1 caused changes in gene expression enriched in myeloid cell differentiation signatures (Fig. 3 C; Krivtsov et al., 2006; Hahn et al., 2009). Consistent with this result, we found decreased c-Kit expression on the surface of leukemia cells expressing Csnk1a1 shRNAs (Fig. 3 D).

Because decreased Rps6 phosphorylation causes activation of p53 (Khalaileh et al., 2013) and Csnk1a1 may also regulate p53 through other mechanisms, we hypothesized that p53 is a leukemia cells in Tp53+/− and Tp53−/− background were transduced with vectors coexpressing GFP and Control-sh or Csnk1a1-sh1. The GFP percentage was measured 2 (input) and 7 d after transduction. Data are presented as the GFP percentage normalized to the input measurement (n = 3). (F) 200,000 sorted GFP+ Tp53+/− leukemia cells carrying Control-sh or Csnk1a1-sh1 were transplanted into wild-type recipient mice. Survival of the mice is shown in Kaplan–Meier curves (six mice per group; each mouse was injected with leukemia cells from independent transductions). (G) Leukemia cells carrying shRNAs were analyzed for early (Annexin V+ Hoechst 33342−) and late (Annexin V+ Hoechst 33342+) apoptotic cells (n = 3). (H) Cell cycle analysis on leukemia cells carrying shRNAs (n = 3). Means and SD are shown (**, P < 0.01; ***, P < 0.001).
critical mediator of the effects of Csnk1a1 suppression in leukemia. To test this hypothesis, we generated MLL-AF9 leukemia in a Tp53−/− background. We found that Tp53−/− leukemia cells were resistant to the effects of Csnk1a1 silencing, both in vitro and in vivo (Fig. 3, E and F). These findings demonstrate that p53 function is essential for the antileukemic effects of Csnk1a1 knockdown. Consistent with p53 activation, Csnk1a1 knockdown induced apoptosis and cell cycle arrest (Fig. 3, G and H; and Figs. S1 and S2).

To explore the potential therapeutic efficacy of targeting Csnk1a1, we tested whether D4476, a selective small molecule inhibitor of casein kinase 1 (Rena et al., 2004; Anastassiadis et al., 2011), would exhibit antileukemic effects. Treatment of primary c-Kit+/high leukemia cells in vitro with D4476 killed the leukemia cells with an EC50 of 6.5 µM, whereas concentrations up to 40 µM had minimal effects on normal HSPCs and Tp53−/− leukemia cells under similar culture conditions (Fig. 4 A).

To address whether D4476 killed c-Kit+/high leukemia cells by inhibiting Csnk1a1, we decreased expression of Csnk1a1 using shRNAs and demonstrated that these cells were sensitized to D4476 in a dose-dependent manner (Fig. 4 B). Conversely, overexpression of Csnk1a1 decreased the sensitivity of leukemia cells to D4476 treatment, indicating that D4476 kills leukemia cells via on-target inhibition of Csnk1a1 (Fig. 4 C).

To examine the effect of D4476 on normal and malignant stem cells, we mixed 10,000 LSK cells with 10,000 c-Kit+/high leukemia cells and treated them together, ex vivo, with D4476 for 48 h and then injected the cells into lethally irradiated recipient mice. We found that the mice receiving DMSO control–treated cells died rapidly from aggressive leukemia. In contrast, mice receiving D4476-treated cells survived significantly longer, and one third of these mice remained disease free for the 16-wk duration of the experiment (Fig. 4 D). Additionally, the normal HSPCs were unaffected by the inhibitor and thus contributed robustly to donor cell chimerism, indicating a selective toxicity toward the LSCs over the normal HSPCs (Fig. 4 E).

We next validated that Csnk1a1 is essential for human leukemia cells. Using MLL-ENL–transformed cord blood cells, M9 cells (Barabé et al., 2007), we found that expression of Csnk1a1 shRNAs successfully decreased Csnk1a1 expression and caused rapid depletion of leukemia cells (not depicted). In agreement with the mouse data, M9 cells were sensitive to D4476, whereas human cord blood CD34+ cells were insensitive to treatment (Fig. 4 F).

Our experiments suggest that Csnk1a1 is essential for mouse and human AML cells and that the Csnk1a1 domain requires the Csnk1a1 kinase domain. Partial depletion of Csnk1a1 activity via shRNA knockdown or small molecule inhibition resulted in a pronounced therapeutic window with a selective loss of the leukemia population. Consistent with previous studies linking Csnk1a1 to suppression of p53 (Chen et al., 2005; Huart et al., 2009; Elyada et al., 2011), we found that lack of Rps6 phosphorylation and induction of p53 is a major consequence of Csnk1a1 loss in leukemia cells leading to enforced cell differentiation. In addition, increased expression of β catenin, downstream of Csnk1a1 inhibition, has also been shown to induce p53 (Damalas et al., 2001), and Csnk1a1 can regulate p53 by binding to MDM2 (Huart et al., 2009). Our findings suggest that targeting of Csnk1a1 provides a potential approach to the therapeutic activation of p53 in AML, a disorder predominantly associated with nonmutated Tp53 (Patel et al., 2012).

**MATERIALS AND METHODS**

**Leukemia model.** All animal experiments were conducted with an Institutional Animal Care and Use Committee–approved protocol. Mouse MLL-AF9 leukemias in a dsRed transgenic background (6051; The Jackson Laboratory) were generated as previously described (Miller et al., 2013). To enrich for LSCs, femurs and tibias from leukemic mice were first harvested, crushed, and filtered, and red blood cells were lysed using lysis buffer (BD). Then BM cells were stained with APC-conjugated anti-c-Kit (clone 2B8; eBioscience) and dsRed+ c-Kit+/high cells (20%) were sorted (FACSaria II; BD). MLL-AF9–driven Tp53−/− leukemias were generated from c-Kit−/−enriched BM cells from Tp53−/−/− mice (002101; The Jackson Laboratory).

**Cell cultures and transductions.** Sorted c-Kit+/high leukemia cells were plated in RPMI-1640 (Sigma-Aldrich) medium supplemented with 1% l-glutamine, 1% penicillin and streptomycin, and 10% fetal bovine serum (Invitrogen) in 10 ng/ml mouse IL-3 (mIL-3; PeproTech). For isolation of LSK cells, c-Kit+–positive cells were first isolated using MACS beads (Miltenyi Biotec), followed by antibody staining and sorting for lineage−, Sca−1+, and c-Kit+ cells. For transductions of leukemia cells, the medium was also supplemented with 10 ng/ml mIL-6, 20 ng/ml mouse stem cell factor (mSCF), and 5 µg/ml polybrene (Sigma-Aldrich). Virus-containing medium was mixed with cells, and spinfection was performed at 2,500 rpm for 90 min at 37°C. Lentiviral vectors were pseudotyped with VSV-G envelope, whereas oncoretroviral vectors were pseudotyped with ecotropic envelope and produced using standard protocols. For LSK cells, sorted cells were put in StemSpan Serum-Free Expansion Medium (STEMCELL Technologies) supplemented with 100 ng/ml mouse thrombopoietin (mTpo; PeproTech) and 100 ng/ml mSCF (PeproTech). LSK cells were prestimulated for 24 h and transduced using spinoculation as described above. In the Csnk1a1 and Rps6 rescue experiments, leukemia cells were first transduced with the retroviral MIG vectors and then after 24 h subjected to an additional transduction with lentiviral vectors expressing shRNAs, and then 24 h later, puromycin was added to the medium at 0.5 µg/ml. M9 cells were cultured in αlfa Mem (Life Technologies) medium supplemented with 10% human plasma (Sigma-Aldrich), 20% FBS, 1% l-glutamine, 1% penicillin and streptomycin, 100 ng/ml mSCF (PeproTech), 10 ng/ml IL-3 (PeproTech), 5 ng/ml IL-7 (PeproTech), 5 ng/ml Flt3L (PeproTech), 50 µg/ml Gentamicin (Life Technologies), and 1 µg/ml heparin (Sigma-Aldrich).

**Drug treatment using D4476.** For inhibition of Csnk1a1, the small molecule D4476 (Tocris Bioscience) was used. D4476 was added to leukemia cells cultured in 96-well plates (5,000 cells per well) in medium supplemented with 10 ng/ml mIL-3. A D4476 dose titration was performed by adding 2.5 µM, 5 µM, 10 µM, 20 µM, and 40 µM D4476 to cell cultures in a final DMSO percentage of 0.4%. Similarly, D4476 was added to LSK cells cultured in SFEM medium supplemented with mTpo and mSCF. The number of cells after 96 h of treatment was assessed with CountBright absolute counting beads (Invitrogen) using flow cytometry.

**Microarray analysis.** Global gene expression profiling of c-Kit+/high leukemia cells was performed on sorted GFP+ cells, harvested 72 h after transduction with lentiviral vectors coexpressing shRNAs and GFP RNA was extracted using TRIzol (Invitrogen), and samples were analyzed using Mouse WG-6 version 2.0 Expression BeadChip (Illumina). Enrichment of gene expression signatures was analyzed using Gene Set Enrichment Analysis (GSEA; Subramanian et al., 2005). Raw data and normalized gene expression data
Leukemic granulocyte macrophage progenitors (GMPs; Lin<sup>-</sup>Sca-1<sup>-</sup>, c-KIT<sup>+</sup>, FcγRII<sup>−</sup>, CD34<sup>+</sup>, CD13<sup>+</sup>, CD38<sup>−</sup>, cd<sup>R29</sup>), transduced with Control-sh or Csnk1a1-sh1, were harvested 72 h after transduction and washed in PBS. Then, GMPs were resuspended in fixation medium (reagent A, fix and perm kit; Invitrogen) for 10 min at room temperature in the dark. After another washing step, cells were resuspended in the permeabilization medium (reagent B, fix and perm and Knorr kit; Invitrogen) for 20 min at room temperature. After another washing step, cells were stained with Hoechst 33342 according to the manufacturer's instructions and resuspended in flow buffer. Cells were subsequently analyzed using the FACS LSRII.

After washing, cells were stained with secondary antibody (Ki67-APC; 1:20; BioLegend). The relative quantity of specific transcripts was calculated using the ΔΔCT method and normalized to Gapdh as endogenous control. Triplicate samples were used.

Cell cycle analysis. Leukemic GMPs were transduced with Control-sh or Csnk1a1-sh1, harvested 72 h later, and washed in PBS. Cells were then washed in 1× binding buffer (BD) and stained in 1× binding buffer in the presence of Annexin V–directly conjugated primary antibody for 20 min at room temperature (Annexin V–APC; BD). After another washing step, cells were stained with Hoechst 33342 according to the manufacturer's instructions and resuspended in flow buffer. Cells were subsequently analyzed using the FACS LSRII.

**Homening experiment.** Leukemia cells were transduced with Control-sh, Csnk1a1-sh1, or Csnk1a1-sh2 coexpressing GFP and transplanted into sublethally irradiated mice 48 h after transduction. 24 h after transplantations, BM cells were harvested, and the percentage of GFP<sup>+</sup> cells was determined using flow cytometric analysis within the dsRed<sup>+</sup> cells. The percentage of GFP<sup>+</sup> cells in corresponding in vitro cultured cells was measured 72 h after transduction.

**Ex vivo drug treatment of leukemia and LSK cells on mesenchymal stroma.** LSK cells and c-Kit<sup>high</sup> leukemia cells were mixed and added onto BM mesenchymal stromal cells (BMSCs) derived from actin-GFP mice (000329; The Jackson Laboratory). The mesenchymal stroma cells were prepared by plating RBC-lysed, freshly isolated BM cells in BMSC medium (400 ml α-MEM [STEMCELL Technologies], 20% FBS [HyClone], and 5 ml Pen-Strep [CellGro]). Cells were grown in flasks in a 33°C/5% CO<sub>2</sub> temperature. After 24 h incubation at 37°C, one third of the cells were harvested and frozen in PBS. Remaining cells were injected into sublethally irradiated recipient mice. 14 d after transplantation, mice were sacrificed, BM and spleens were harvested, and cells were put in PBS and frozen before genomic DNA isolation, PCR, and Illumina sequencing. The depletion of individual shRNAs was compared with the pre-injection time point and with the shRNA controls.

**shRNA screening.** The shRNA screen was performed essentially as previously described (Miller et al., 2013). In brief, 2 × 10<sup>4</sup> sorted c-Kit<sup>high</sup> leukemia cells were isolated and immediately transduced with a pool of lentiviral shRNAs using spinfection as described above. Five replicates with separate transductions were performed. After 24 h incubation at 37°C, one third of the cells were harvested and frozen in PBS. Remaining cells were injected into sublethally irradiated recipient mice. 14 d after transplantation, mice were sacrificed, BM and spleens were harvested, and cells were put in PBS and frozen before genomic DNA isolation, PCR, and Illumina sequencing. The depletion of individual shRNAs was compared with the pre-injection time point and with the shRNA controls.

**Statistical analysis.** Kaplan–Meier curves were generated using Prism 5 software (GraphPad Software). In all figures, the mean values and SDs are shown. P-values were calculated using the Student’s test or the Mantel–Cox (for Kaplan–Meier curves only) test. Significance is depicted with asterisks: *, P < 0.05; **, P < 0.01; ***, P < 0.001. For further details, see corresponding figure legends.

**Online supplemental material.** Fig. S1 shows the gating strategy for Fig. 3 G. Fig. S2 shows the gating strategy for Fig. 3 H. Table S1 is a gene list showing the number of shRNAs that depleted leukemia cells >40-fold in BM and spleen. Online supplemental material is available at http://www.jem.org/cgi/content/full/jem.20131033/DC1.

M. Järäs was sponsored by a postdoctoral scholarship from the Swedish Childhood Cancer Foundation. B.L. Eriä was supported by the National Institutes of Health (grants R01HL082945 and P01 CA108631), a Leukemia and Lymphoma Society Scholar Award, and the Gabrielle’s Angel Foundation. The authors declare no competing financial interests.

Submitted: 18 May 2013
Accepted: 18 February 2014

**REFERENCES**


Csnk1a1 is a therapeutic target in AML | Järås et al.


